Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted radiation approach reach brain tumors from breast cancer?

NCT ID NCT06611306

Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 08, 2026 · Last updated Oct 09, 2026 · Updated 1 time

Summary

Researchers are testing a focused, dose-escalated radiotherapy technique called DE-iPTV in adults with breast cancer that has spread to the brain. The trial enrolls people who would normally receive whole-brain radiotherapy. Participants receive five radiotherapy doses and complete quality-of-life questionnaires and steroid diaries for up to 24 weeks. The study checks whether the technique can be delivered as planned and whether it affects quality of life, tumor control, and steroid use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dose-escalated VMAT-based radiotherapy (DE-iPTV)
What this could lead to
If it works, this could offer a more targeted radiotherapy option for people whose breast cancer has spread to the brain and who cannot have stereotactic radiotherapy.
What could go wrong
This is a small, single-arm pilot with 42 participants and no comparison group, so it cannot prove the approach works better than standard whole-brain radiotherapy. Radiotherapy to the brain carries risks of tiredness, hair loss, and short-term swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up 2. Adult (aged 16+) patients, resident in the United Kingdom. 3. Histologically confirmed primary breast cancer with brain metastases on MRI imaging 4. The treating oncologist considers whole-brain radiotherapy to be the most suitable treatment outside of the trial. 5. Eastern Cooperative Oncology Group Performance status 0, 1 or 2 6. Able to respond to question about their quality of life, symptoms, and side effects remotely (via telephone assessments 7. Life expectancy from extra-cranial disease \>3 months Exclusion Criteria 1. Leptomeningeal disease 2. "Miliary" pattern of metastases: patients with over 15 metastases are excluded (clinician-based assessment) 3. Cystic metastases 4. Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable) 5. Plan for hippocampal-sparing whole brain radiotherapy. 6. Unable to give informed consent. 7. Prognosis less than 3 months 8. Pregnant or nursing women 9. Unable to complete a brain MRI and/or known allergy to gadolinium.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases, adult are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases, adult Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Imperial College London

    RECRUITING

    London, London, SW7 2AZ, United Kingdom

  • University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford,

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.